latest update:
[TrialBase DB]

trial summary · NCT05555550

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Glioma, sponsored by Children's Hospital of Philadelphia. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT05555550phase EARLY_PHASE1enrollment 30start 2026-11-29

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.

Source record: https://clinicaltrials.gov/study/NCT05555550

Facts

registry idNCT05555550
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phaseEARLY_PHASE1
study typeINTERVENTIONAL
lead conditionGlioma
sponsorChildren's Hospital of Philadelphia
sponsor classOTHER
enrollment30
start date2026-11-29
primary completion2027-12
completion2028-09
results postednot reported

Conditions

  • Glioma
  • Low-grade Glioma
  • Low Grade Glioma of Brain
  • Glioma, Malignant
  • Glioma Intracranial

Interventions

  • 18F-Fluciclovine

Countries

  • United States

Intervention types: DRUG

Work with this record